{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:34:35Z","timestamp":1789655675122,"version":"4.0.1"},"reference-count":56,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: Prostate biopsy is associated with a risk of significant infectious complications including sepsis. We investigated the risk of infections after transrectal (TR) biopsy compared to transperineal (TP) biopsy.Materials and methods: Men who had undergone prostate biopsy and diagnosed with prostate cancer were identified in the National Prostate Cancer Register (NPCR) of Sweden. Linkage with Swedish health care registers provided information on hospitalization, antibiotic prescriptions and comorbidities. Rate ratios for hospitalization, for infections, after TR and TP biopsies over day 1\u20137, 1\u201314, and 1\u201330 were estimated with Poisson regression. Filled prescriptions for urinary tract related antibiotics were also assessed.Results: Thirty-one thousand two hundred twenty-two men underwent biopsy between 1 January 2020 and 31 December 2023. 87% underwent TR and 13% TP biopsy.Hospitalization occurred in 0.6% of men (n = 24) after TP biopsy and 2.0% (n = 548) after TR biopsy. Rate ratios for hospitalization in the TR group compared to TP were 8.0 (95% confidence interval [CI]: 4.0\u201316.2) for day 1\u20137, 6.2 (3.2\u201311.9) for day 1\u201314, and 4.1 (2.4\u20136.8) for day 1\u201330. Filled antibiotic prescriptions were found for 4.5% of men (n = 187) after TP biopsy and 6.9% (n = 1,883) after TR biopsy. For antibiotic prescriptions, the rate ratios were 2.3 (1.8\u20132.9) for day 1\u20137 as well as day 1\u201314, and 1.6 (1.3\u20131.9) for day 1\u201330.\nConclusions: A transrectal prostate biopsy was associated with a significantly higher risk of post-biopsy infectious complications compared to transperineal biopsy. These findings support the use of transperineal biopsy.<\/jats:p>","DOI":"10.2340\/sju.v61.45537","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:53:30Z","timestamp":1773748410000},"page":"44-50","source":"Crossref","is-referenced-by-count":2,"title":["Risk of infectious complications after transperineal prostate biopsy compared to transrectal biopsy: nationwide population-based cohort study in Sweden"],"prefix":"10.2340","volume":"61","author":[{"given":"Jesper","family":"Bonnedahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Johan","family":"Lundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Stranne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Wagenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"\u00d6rtegren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Holmbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Styrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"144833","doi-asserted-by":"crossref","unstructured":"Borghesi M, Ahmed H, Nam R, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71(3):353\u2013365.","DOI":"10.1016\/j.eururo.2016.08.004"},{"key":"144834","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2016.08.004","DOI":"10.1016\/j.eururo.2016.08.004"},{"key":"144835","doi-asserted-by":"crossref","unstructured":"Liss MA, Ehdaie B, Loeb S, et al. An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol. 2017;198(2):329\u2013334.","DOI":"10.1016\/j.juro.2017.01.103"},{"key":"144836","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.juro.2017.01.103","DOI":"10.1016\/j.juro.2017.01.103"},{"key":"144837","doi-asserted-by":"crossref","unstructured":"Roberts MJ, Bennett HY, Harris PN, et al. Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches. Urology. 2017;104:11\u201321.","DOI":"10.1016\/j.urology.2016.12.011"},{"key":"144838","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.urology.2016.12.011","DOI":"10.1016\/j.urology.2016.12.011"},{"key":"144839","doi-asserted-by":"crossref","unstructured":"\u00d6rtegren J, Kohestani K, Elvstam O, et al. Risk factors for infection after transrectal prostate biopsy: a population-based register study. Eur Urol Open Sci. 2024;67:1\u20136.","DOI":"10.1016\/j.euros.2024.06.015"},{"key":"144840","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euros.2024.06.015","DOI":"10.1016\/j.euros.2024.06.015"},{"key":"144841","doi-asserted-by":"crossref","unstructured":"Ljungquist O, Persmark A, Grabe M, et al. Increasing rates of urinary and bloodstream infections following transrectal prostate biopsy in South Sweden. BJU Int. 2022;130(4):478\u2013485.","DOI":"10.1111\/bju.15713"},{"key":"144842","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.15713","DOI":"10.1111\/bju.15713"},{"key":"144843","doi-asserted-by":"crossref","unstructured":"Lundstr\u00f6m KJ, Drevin L, Carlsson S, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014;192(4):1116\u20131122.","DOI":"10.1016\/j.juro.2014.04.098"},{"key":"144844","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.juro.2014.04.098","DOI":"10.1016\/j.juro.2014.04.098"},{"key":"144845","doi-asserted-by":"crossref","unstructured":"Bennett HY, Roberts MJ, Doi SA, et al. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect. 2016;144(8):1784\u20131791.","DOI":"10.1017\/S0950268815002885"},{"key":"144846","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1017\/S0950268815002885","DOI":"10.1017\/S0950268815002885"},{"key":"144847","doi-asserted-by":"crossref","unstructured":"Xiang J, Yan H, Li J, et al. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;17(1):31.","DOI":"10.1186\/s12957-019-1573-0"},{"key":"144848","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12957-019-1573-0","DOI":"10.1186\/s12957-019-1573-0"},{"key":"144849","doi-asserted-by":"crossref","unstructured":"Newman TH, Stroman L, Hadjipavlou M, et al. EXIT from Transrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy. Prostate Cancer Prostatic Dis. 2022;25(2):283\u2013287.","DOI":"10.1038\/s41391-021-00438-w"},{"key":"144850","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41391-021-00438-w","DOI":"10.1038\/s41391-021-00438-w"},{"key":"144851","doi-asserted-by":"crossref","unstructured":"Stangl-Kremser J, Ramaswamy A, Hu JC. Transperineal vs. transrectal biopsy to reduce post interventional sepsis. Curr Opin Urol. 2023;33(3):193\u2013199.","DOI":"10.1097\/MOU.0000000000001083"},{"key":"144852","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MOU.0000000000001083","DOI":"10.1097\/MOU.0000000000001083"},{"key":"144853","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6."},{"key":"144854","doi-asserted-by":"crossref","unstructured":"Hu JC, Assel M, Allaf ME, et al. Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol. 2024:S0302-2838(23)03342-0. tps:\/\/doi:10.1016\/j.eururo.2023.12.015","DOI":"10.1016\/j.eururo.2023.12.015"},{"key":"144855","doi-asserted-by":"crossref","unstructured":"Mian BM, Feustel PJ, Aziz A, et al. Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC randomized clinical trial. J Urol. 2024;211(2):205\u2013213.","DOI":"10.1097\/JU.0000000000003788"},{"key":"144856","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/JU.0000000000003788","DOI":"10.1097\/JU.0000000000003788"},{"key":"144857","doi-asserted-by":"crossref","unstructured":"Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158\u2013163.","DOI":"10.3109\/0284186X.2014.939299"},{"key":"144858","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/0284186X.2014.939299","DOI":"10.3109\/0284186X.2014.939299"},{"key":"144859","doi-asserted-by":"crossref","unstructured":"Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27\u201333.","DOI":"10.1080\/02841860802247664"},{"key":"144860","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/02841860802247664","DOI":"10.1080\/02841860802247664"},{"key":"144861","doi-asserted-by":"crossref","unstructured":"Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190\u2013192.","DOI":"10.2340\/sju.v59.42272"},{"key":"144862","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v59.42272","DOI":"10.2340\/sju.v59.42272"},{"key":"144863","doi-asserted-by":"crossref","unstructured":"Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: the National Prostate Cancer Register of Sweden and prostate cancer data base \u2013 a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73\u201382.","DOI":"10.1093\/ije\/dyv305"},{"key":"144864","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ije\/dyv305","DOI":"10.1093\/ije\/dyv305"},{"key":"144865","doi-asserted-by":"crossref","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","DOI":"10.1186\/1471-2458-11-450"},{"key":"144866","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1471-2458-11-450","DOI":"10.1186\/1471-2458-11-450"},{"key":"144867","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u2013383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"144868","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"144869","doi-asserted-by":"crossref","unstructured":"Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register \u2013 opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u2013735.","DOI":"10.1002\/pds.1294"},{"key":"144870","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/pds.1294","DOI":"10.1002\/pds.1294"},{"key":"144871","doi-asserted-by":"crossref","unstructured":"Gedeborg R, Sund M, Lambe M, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607\u2013615.","DOI":"10.1097\/EDE.0000000000001358"},{"key":"144872","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/EDE.0000000000001358","DOI":"10.1097\/EDE.0000000000001358"},{"key":"144873","doi-asserted-by":"crossref","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765\u2013773.","DOI":"10.1007\/s10654-017-0316-1"},{"key":"144874","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10654-017-0316-1","DOI":"10.1007\/s10654-017-0316-1"},{"key":"144875","unstructured":"Classification of Surgical Procedures 1997 (KK\u00c5) [Internet]. The National Board of Health and Welfare; 2004 [cited 2023 Oct 23]. Available from:https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/klassifikationer-och-koder\/kkakum2005-2020.pdf"},{"key":"144876","doi-asserted-by":"crossref","unstructured":"Forsvall A, J\u00f6nsson H, Wagenius M, et al. Rate and characteristics of infection after transrectal prostate biopsy: a retrospective observational study. Scand J Urol. 2021;55(4):317\u2013323.","DOI":"10.1080\/21681805.2021.1933169"},{"key":"144877","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2021.1933169","DOI":"10.1080\/21681805.2021.1933169"},{"key":"144878","doi-asserted-by":"crossref","unstructured":"Lam W, Wong AHG, Chun S, et al. P0999 \u2013 prostate cancer detection, tolerability and safety of transperineal prostate biopsy under local-anaesthesia versus standard transrectal biopsy in biopsy-na\u00efve men: a pragmatic, parallel group, randomized-controlled study. Eur Urol. 2021;79(S1):S1405. ISSN 0302-2838.","DOI":"10.1016\/S0302-2838(21)01372-5"},{"key":"144879","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0302-2838(21)01372-5","DOI":"10.1016\/S0302-2838(21)01372-5"},{"key":"144880","doi-asserted-by":"crossref","unstructured":"Styrke J, Resare S, Lundstr\u00f6m KJ, et al. Current routines for antibiotic prophylaxis prior to transrectal prostate biopsy: a national survey to all urology clinics in Sweden. F1000Res. 2020;9:58.","DOI":"10.12688\/f1000research.19260.1"},{"key":"144881","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.12688\/f1000research.19260.1","DOI":"10.12688\/f1000research.19260.1"},{"key":"144882","unstructured":"Swedres-Svarm. 2023. Sales of antibiotics and occurrence of antibiotic resistance in Sweden. Solna\/Uppsala. ISSN 2001-7901 Available at: www.sva.se\/swedres-svarm\/"},{"key":"144883","unstructured":"Antibiotic prophylaxis in urological surgery [Internet] Swedish Urology Association; 2023 [cited 2025 Jun 15]. Available from: https:\/\/strama-nationell.infosynk.se\/category\/profylax Accessed 2024-04-24"},{"key":"144884","doi-asserted-by":"crossref","unstructured":"Bratt O, Carlsson S, Fransson P, et al. Swedish National Prostate Cancer Guidelines Group. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265\u2013273.","DOI":"10.1080\/21681805.2022.2094462"},{"key":"144885","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2094462","DOI":"10.1080\/21681805.2022.2094462"},{"key":"144886","doi-asserted-by":"crossref","unstructured":"Berg S, Tully KH, Hoffmann V, et al. Assessment of complications after transperineal and transrectal prostate biopsy using a risk-stratified pathway identifying patients at risk for post-biopsy infections. Scand J Urol. 2023;57(1\u20136):41\u201346.","DOI":"10.1080\/21681805.2023.2168049"},{"key":"144887","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2023.2168049","DOI":"10.1080\/21681805.2023.2168049"},{"key":"144888","doi-asserted-by":"crossref","unstructured":"Bryant RJ, Marian IR, Williams R, et al; TRANSLATE Trial Study Group. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. Lancet Oncol. 2025;26(5):583\u2013595.","DOI":"10.1016\/S1470-2045(25)00100-7"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45537\/53176","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45537\/53176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:53:38Z","timestamp":1773748418000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/45537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":56,"URL":"https:\/\/doi.org\/10.2340\/sju.v61.45537","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}